Wockhardt is focusing on developing new antibiotics in the US market, abandoning generics. Their novel antibiotic, Zaynich, shows promising results and seeks FDA approval. This strategy targets a large market vacated by Big Pharma, aiming for 10-year exclusivity. The shift aims to improve profitability and reduce dependence on the volatile US generics market, with a focus on emerging markets for generics.
